Verra transforms the treatment of protease-driven diseases, from COPD to cancer, using an innovative small protein platform. Verras lead inhibitor, VTH140, is a small protein which will allow immunotherapies to benefit more patients by revitalizing antigen availability. Tumor proliferative factors are also brought under control with the administration of VTH140 and it promises excellent synergy with chemotherapy (as shown). Across numerous indications and modalities, Verra intends to leverage and amplify the power of emerging anti-cancer therapies.
